REGOBONE

NCT02389244 📎

Regimen

Experimental
Regorafenib 160 mg/d
Control
Placebo with crossover on progression

Population

Metastatic osteosarcoma progressing after >=1 prior chemo line, age >=10

Key finding

Independent European replication of SARC024. Regorafenib delayed progression but did not produce RECIST responses. Combined with SARC024 the result is as convincing as 80-patient data gets in this rare disease.

Source: PMID 30477937

Timeline

    Guideline citations

    • NCCN BONE (p.77)